Company news
Nuvectis Pharma, Inc. (NASDAQ:NVCT) news
Every Nuvectis Pharma, Inc. press release and news update in one place — announcements, filings coverage, and company updates for investors.
Press releases & updates
Nuvectis Pharma To Participate in Upcoming Investor Conferences
September 3, 2026
Nuvectis Pharma Reports Second Quarter 2026 Financial Results and Business Highlights
August 4, 2026
Ciprocopan (NXP100) Receives Marketing Approval in China for the Treatment of Patients with PNH Previously Untreated with Complement Inhi...
July 23, 2026
Correction: (Title Correction) Nuvectis Announces Marketing Approval of Ciprocopan (NXP100) in China for the Treatment of Patients with P...
July 23, 2026
Nuvectis Pharma Announces Pricing of $100 Million Public Offering of Common Stock
June 29, 2026
Nuvectis Announces Strategic Portfolio Expansion via License Agreement for Ex-China Rights with Haisco Pharmaceutical Group for Two Poten...
June 22, 2026
Nuvectis Lands Major Haisco Deal for Two Potentially Best-in-Class Compounds in Multi-Billion-Dollar Markets
June 22, 2026
Nuvectis Pharma, Inc. Reports First Quarter 2026 Financial Results and Business Highlights
May 5, 2026
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2026 American Association for Cancer Research Meeting
March 31, 2026
Nuvectis Pharma, Inc. Reports 2025 Financial Results and Business Highlights
February 11, 2026
Nuvectis Pharma Announces the Initiation of the Phase 1b Study of NXP900 in Combination with Osimertinib in Patients with NSCLC
December 17, 2025
Nuvectis Pharma to Host a Virtual Key Opinion Leader Meeting to Discuss the NXP900 Phase 1b Program in Advanced Solid Tumors, Including t...
November 25, 2025
CORRECTION: Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
November 4, 2025
Nuvectis Pharma, Inc. Reports Third Quarter 2025 Financial Results and Business Highlights
November 4, 2025
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR-NCI-EORTC International Conference on Molecular Tar...
October 27, 2025
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 AACR-NCI-EORTC International Conference on Molecular Targets and ...
October 16, 2025
Nuvectis Pharma Appoints Biotech Executive Juan Sanchez, MD, to the Board of Directors
September 25, 2025
Nuvectis Pharma to Participate at the H.C. Wainwright 27th Annual Global Investment Conference
September 4, 2025
Nuvectis Pharma Announces the Initiation of the Phase 1b Program for NXP900
August 11, 2025
Nuvectis Pharma, Inc. Reports Second Quarter 2025 Financial Results and Business Highlights
August 5, 2025
Nuvectis Pharma Provides Final Clinical Data Update from the NXP800 Phase 1b Study in Ovarian Cancer and Reports Completion of the NXP900...
July 31, 2025
Nuvectis Pharma Announces Successful Completion of a Drug-Drug Interaction Study in Healthy Volunteers Supporting NXP900's Potential as a...
July 8, 2025
Nuvectis Pharma to Present at the H.C. Wainwright BioConnect Investor Conference
May 16, 2025
Nuvectis Pharma, Inc. Reports First Quarter 2025 Financial Results and Business Highlights
May 6, 2025
Nuvectis Pharma Provides Poster Presentation Highlights for NXP900 from the 2025 AACR Meeting
April 29, 2025
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2025 American Association for Cancer Research Meeting
March 26, 2025
Nuvectis Pharma to Participate in the 37th Annual Roth Conference
March 14, 2025
Nuvectis Pharma Announces a New Publication of a Research Study Demonstrating that the Combination of NXP900 and EGFR Inhibitors Improves...
March 4, 2025
Nuvectis Pharma, Inc. Reports 2024 Financial Results and Business Highlights
February 25, 2025
Nuvectis Pharma Announces Closing of $15.5 Million Public Offering of Common Stock and Full Exercise of Underwriter’s Over-Allotment Option
February 7, 2025
Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock
February 5, 2025
Nuvectis Pharma Announces Proposed Public Offering of Common Stock
February 4, 2025
Nuvectis Pharma to Present at the 2024 Ladenburg Virtual Oncology Innovators & Investors Symposium
December 10, 2024
Nuvectis Pharma Reports Encouraging NXP800 Interim Data Supporting Ongoing Enrollment in Phase 1b Study in Patients with Platinum-Resista...
November 14, 2024
Nuvectis Pharma, Inc. Reports Third Quarter 2024 Financial Results and Business Highlights
November 5, 2024
Nuvectis Pharma Announces Upcoming Presentations for NXP900 at the 2024 AACR-NCI-EORTC Symposium on Molecular Targets and Cancer Therapeu...
October 23, 2024
Nuvectis Pharma to Participate in the 3rd Annual ROTH Healthcare Opportunities Conference
October 7, 2024
Nuvectis Pharma to Present at the H.C. Wainwright 26th Annual Global Investment Conference
September 5, 2024
Nuvectis Pharma Announces Orphan Drug Designation Granted by the FDA for NXP800 for the Treatment of ARID1a-deficient Ovarian, Fallopian ...
August 29, 2024
Nuvectis Pharma, Inc. Reports Second Quarter 2024 Financial Results and Business Highlights
August 6, 2024
Nuvectis Pharma, Inc. to Present at the H.C. Wainwright BioConnect Investor Conference
May 16, 2024
Nuvectis Pharma, Inc. Reports First Quarter 2024 Financial Results and Business Highlights
May 7, 2024
Nuvectis Pharma's NXP900 Demonstrates Robust Activity in Non-Small Cell Lung Cancer Cell Lines
April 8, 2024
Nuvectis Pharma Announces Upcoming Presentations at the 2024 American Association for Cancer Research Meeting
March 19, 2024
Nuvectis Pharma to Present at the 36th Annual Roth Conference
March 15, 2024
Nuvectis Pharma Announces Encouraging Preliminary Data from the NXP800 Phase 1b Clinical Trial in Platinum-Resistant ARID1a-Mutated Ovari...
March 14, 2024
Nuvectis Pharma, Inc. Reports Fiscal Year 2023 Financial Results and Business Highlights
March 5, 2024
Nuvectis Pharma Announces Participation at Upcoming Investor Conferences
February 9, 2024
Nuvectis Pharma to Present at the 42nd Annual J.P. Morgan Healthcare Conference
January 3, 2024
Nuvectis Pharma, Inc. Announces a Collaboration with Mayo Clinic to Evaluate NXP800 in an Investigator-Sponsored Clinical Trial in Cholan...
December 18, 2023